Quick Answer
Definium Therapeutics, Inc. reported Common Stock Shares Outstanding of 98.78 million shares for the year ending 2025.
- Definium Therapeutics, Inc. showed an increase of +31.5% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Definium Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: 426.69 million shares | Q3 2022: 37.54 million shares | Q1 2023: 38.29 million shares | Q2 2023: 38.81 million shares | Q3 2023: 40.09 million shares | Q1 2024: 71.16 million shares | Q2 2024: 72.08 million shares | Q3 2024: 81.59 million shares | Q1 2025: 75.51 million shares | Q2 2025: 75.80 million shares | Q3 2025: 76.77 million shares.
- Over the full 5 years of available data (2021 to 2025), Definium Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 251.2%.
- Historical annual values: Fiscal year 2025: 98.78 million shares | Fiscal year 2024: 75.10 million shares | Fiscal year 2023: 41.10 million shares | Fiscal year 2022: 37.98 million shares | Fiscal year 2021: 28.13 million shares.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: